Search

Displaying results 3901 - 3910 of 4233 in total
  1. Drug

    Avacopan

    go.drugbank.com/drugs/DB15011
    ApprovedInvestigational

    Anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis (AAV) is a rare (estimated incidence of 3 cases per 100,000 per year) form of "pauci-immune" systemic small-vessel vasculitis typified by the presence of ANCAs in th...

  2. Drug

    Hydrocortisone aceponate

    go.drugbank.com/drugs/DB14538
    InvestigationalVet approved

  3. Drug

    Sulfaguanidine

    go.drugbank.com/drugs/DB13726
    Experimental

    Sulfaguanidine is a sulfonamide antibiotic with antimicrobial and antibacterial activities.

  4. Drug

    POT-4

    go.drugbank.com/drugs/DB06056
    Investigational

    POT-4 is a peptide that specifically inhibits complement activation and is initially being developed for the treatment of age-related macular degeneration (AMD). The investigational drug was under investigation in clinical trial NCT00473...

  5. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  6. Drug

    Resatorvid

    go.drugbank.com/drugs/DB05943
    Investigational

    Resatorvid is an investigational compound designed for the treatment of severe sepsis.

  7. Drug

    Bifeprunox

    go.drugbank.com/drugs/DB04888
    Investigational

    Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.

  8. Drug

    Mevastatin

    go.drugbank.com/drugs/DB06693
    Experimental

    It has served as one of the lead compounds for the development of the synthetic compounds used today. … It was the first discovered agent belonging to the class of cholesterol-lowering medications known as statins.

  9. Drug

    Abivertinib

    go.drugbank.com/drugs/DB15327
    Investigational

    cytokines at once, it may provide more pronounced clinical benefits as compared to agents targeting single pathways (e.g. interleukin-6 inhibitors). … [L17388,L17393] The cytokine storm associated with COVID-19 is thought to contribute to disease progression and is associated with poor outcomes in patients - as abivertinib inhibits the release of multiple

  10. Drug

    UB-612

    go.drugbank.com/drugs/DB16444
    Investigational

    The UB-612 COVID-19 vaccine was developed by United Biomedical Inc Asia in Taipei as the first COVID-19 “multi-tope” protein-peptide vaccine made up of eight rationally designed components[L30653]. … The vaccine incorporates a strong S1-RBD component linked to a single chain fragment region (sFC) of a human IgG1, which facilitates cell attachment and acts as the principal neutralizing domain of the